Absci Corporation is a clinical-stage biopharmaceutical company that uses a generative AI approach to develop antibody therapeutics. The company operates an Integrated Drug Creation platform that combines its Origin-1 generative design model with rapid wet-lab validation to design biologics against difficult-to-drug targets. Its lead product candidate, ABS-201, is an anti-prolactin receptor antibody being developed for androgenetic alopecia and endometriosis. Absci focuses on underexplored biological mechanisms with high unmet medical need, leveraging a continuous feedback loop between AI algorithms and laboratory validation to accelerate drug discovery. The company also advances preclinical programs and seeks partnerships for select pipeline assets.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage absci.com
Sector Healthcare IR page investors.absci.com
Tags
generative ai, antibody therapeutics, drug discovery, synthetic biology, prolactin receptor, androgenetic alopecia, endometriosis, deep learning, protein engineering, Origin-1, ABS-201, HEADLINE, Integrated Drug Creation, SoluPro, ACE assay
Press page absci.com/about-us/press-releases

Metrics

Valuation  
Market cap $ 1.86B
Market cap (USD) $ 1.86B
P/E -13.81
PEG —
P/BV 8.51
P/S —
P/OCF -16.53
P/FCF -16.54
Dividend yield —
Turnover / mcap —
Returns  
ROE -62.5%
ROI -60.5%
ROIC -47.4%
Profit margin -4,113.7%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 27
Quality score -82.4%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue 2.8M 4.534M 5.718M 4.529M 4.009M 4.117M
Net profit -115.183M -103.106M -110.566M -104.904M -100.96M -14.353M
Free cash flow -94.032M -72.806M -65.496M -97.514M -98.645M -13.151M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Share price 3.49 2.62 4.2 2.1 8.2 —
Price performance 12m 0.33 -0.38 1 -0.74 — —

Filed figures

Figure Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — — — — 2.19M 0.00 —
↳ YoY growth -100.0%
Lease liabilities (USD) — 8.82M 16.5M 12.1M 8.04M 6.12M 4.43M
Cash and deposits (USD) 13.9M 69.9M 253M 60M 72.4M 41.2M 20M
Intangible assets (USD) — 0.00 55M 51.6M 48.3M 44.9M 41.5M
Right-of-use assets (USD) — 4.48M 6.54M 5.32M 4.49M 3.97M 2.91M
Cash flow detail
Operating cash flow (USD) — -11M -60.6M -81.3M -64.6M -72.4M -92.9M
Purchases of property, plant and equipment (USD) — -2.18M -38M -16.2M -860,000 -404,000 -1.11M
Change in receivables (cash effect) (USD) — — — — -666,000 2.24M 0.00
Change in payables (cash effect) (USD) — 903,000 1.57M -533,000 -786,000 2.03M 1.09M
Interest paid (cash effect) (USD) — -508,000 -652,000 -895,000 -970,000 -561,000 -178,000
Share-based compensation (USD) — 420,000 10.6M 12.5M 11.4M 19.5M 18.3M
Operating cash flow before change in receivables (USD) — — — — -64M -74.6M -92.9M
Free cash flow (OCF - PPE - intangibles) (USD) — -13.2M -98.6M -97.5M -65.5M -72.8M -94M
Income detail
Research and development expense (USD) — 11.4M 44.6M 58.9M 48.1M 63.9M 81.4M
↳ 5y CAGR +48.0%
Total comprehensive income (USD) — -14.4M -101M -105M -110M -103M -115M
Comprehensive income to owners (USD) — -14.4M -101M -105M -110M -103M -115M
Reported Sep 7, 2021 Mar 22, 2022 Mar 22, 2022 Mar 30, 2023 Mar 18, 2025 Mar 18, 2025 Mar 24, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

ABS-201™ HEADLINE™ trial progressing on track; 13-week interim proof-of-concept data for pattern hair loss (PHL) anticipated next month

Announced preliminary details for Phase 2 STORYLINE™ trial of ABS-201 for endometriosis

Appointed former Galderma executive Gerry Muhle as Chief Commercial Officer

VANCOUVER, Wash. and NEW YORK, November 12, 2026 – Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today reported financial and operating results for the quarter ended September 30, 2026.

“As we approach our first look at proof-of-concept data for ABS-201 next month, followed by full data early next year, we are excited for the opportunity to potentially demonstrate our program's ability to stimulate hair regrowth in a convenient and durable way,” said Sean McClain, Founder and CEO. “As ABS-201 progresses through the clinic, we have begun building our commercial infrastructure to support this and potential future programs.

10/27/2026

PDF Version

VANCOUVER, Wash. and NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the company will be participating in the following upcoming investor conferences:

  • **Guggenheim 3rdAnnual Healthcare Innovation Conference (Boston, MA)**Fireside chat on Tuesday, November 10th at 1:00 p.m. Eastern Time / 10:00 a.m. Pacific Time

  • **2026 Jefferies Global Healthcare Conference (London, England)**Fireside chat on Wednesday, November 18th at 3:00 p.m. Greenwich Mean Time / 10:00 a.m. Eastern Time

  • **9thAnnual Evercore Healthcare Conference (Coral Gables, FL)**Fireside chat on Tuesday, December 1st at 7:30 a.m. Eastern Time / 4:30 a.m. Pacific Time

Interested parties may access live and archived webcasts of the fireside chat sessions on the company’s investor relations website at: investors.absci.com.

About Absci

Absci is advancing the future of drug discovery with generative design to create better biologics for patients, faster. Our Integrated Drug Creation™ platform combines cutting-edge AI models with a synthetic biology data engine, enabling the rapid design of innovative therapeutics that address challenging therapeutic targets. Absci’s approach leverages a continuous feedback loop between advanced AI algorithms and wet lab validation. Each cycle refines our data and strengthens our models, facilitating rapid innovation and enhancing the precision of our therapeutic designs. Alongside collaborations with top pharmaceutical, biotech, tech, and academic leaders, Absci is advancing its own pipeline of AI designed therapeutics including ABS-201™, a groundbreaking innovation in hair regrowth with the potential to redefine treatment possibilities for pattern hair loss. ABS-201 is also being investigated as a potential “best-in-class” therapeutic for endometriosis, a condition with significant unmet medical need and market potential. Absci is headquartered in Vancouver, WA, with AI Research Labs in New York City and Serbia, and an Innovation Center in Switzerland. Learn more at www.absci.com or follow us on LinkedIn (@absci), X (@Abscibio) and YouTube.

Absci® standard character mark, ABS-201™, and Integrated Drug Creation™ are trademarks and registered trademarks of Absci Corporation.

Investor Contact Alexander D.H. Khan Corporate Vice President Head of Investor Relations [email protected]

Media Contact [email protected]

Popup Close

You’re leaving the Absci website. This link is provided for your convenience, but the content is the sole responsibility of its owner. Do you want to continue?

Return to the Absci website at any time by using the “Back” button on your web browser.

YES

NO

Popup Image

10/13/2026

PDF Version

VANCOUVER, Wash. and NEW YORK, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the company will report business updates and financial and operating results for the third quarter 2026 before market open on Thursday, November 12, 2026.

Absci management will webcast a corresponding conference call beginning at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time) to discuss its business developments, financial and operating results, and outlook.

Live audio of the webcast will be available on the company’s investor relations website at: investors.absci.com. The webcast will be archived and available for replay after the event.

About Absci

Absci is advancing the future of drug discovery with generative design to create better biologics for patients, faster. Our Integrated Drug Creation™ platform combines cutting-edge AI models with a synthetic biology data engine, enabling the rapid design of innovative therapeutics that address challenging therapeutic targets. Absci’s approach leverages a continuous feedback loop between advanced AI algorithms and wet lab validation. Each cycle refines our data and strengthens our models, facilitating rapid innovation and enhancing the precision of our therapeutic designs. Alongside collaborations with top pharmaceutical, biotech, tech, and academic leaders, Absci is advancing its own pipeline of AI designed therapeutics including ABS-201™, a groundbreaking innovation in hair regrowth with the potential to redefine treatment possibilities for pattern hair loss. ABS-201 is also being investigated as a potential “best-in-class” therapeutic for endometriosis, a condition with significant unmet medical need and market potential. Absci is headquartered in Vancouver, WA, with AI Research Labs in New York City and Serbia, and an Innovation Center in Switzerland. Learn more atwww.absci.com or follow us on LinkedIn (@absci), X (@Abscibio) andYouTube.

Absci® standard character mark, ABS-201™, and Integrated Drug Creation™ are trademarks and registered trademarks of Absci Corporation.

Investor Contact Alexander D.H. Khan Corporate Vice President Head of Investor Relations [email protected]

Media Contact [email protected]

Popup Close

You’re leaving the Absci website. This link is provided for your convenience, but the content is the sole responsibility of its owner. Do you want to continue?

Return to the Absci website at any time by using the “Back” button on your web browser.

YES

NO

Popup Image

Prompts

Absci Corporation (ticker ABSI), listed in United States.

ETFs Holding Absci Corporation

ETF Weight in ETF Shares Market value As of
ARKG 4.53% 10,883,235 $ 82.495M Nov 18, 2026
SYZ 0.31% 18,412 $ 213.395K Jun 30, 2026
VFMO 0.14% 294,370 $ 2.661M Aug 31, 2026
RESM 0.05% 156 $ 1,808.04 Jun 30, 2026
MSSM 0.01% 10,335 $ 93.428K Aug 31, 2026
DFAS 0.01% 198,854 $ 1.817M Nov 12, 2026
DFAU 0.00% 15,954 $ 145.74K Nov 12, 2026
DFAC 0.00% 104,351 $ 953.246K Nov 12, 2026
DXUV 0.00% 24 $ 219.24 Nov 12, 2026
NTRL short 0.00% -4,867 $ 0.00 Nov 16, 2026